Pravastatin sodium has been launched by Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, under a distribution agreement with Bristol-Myers Squibb Company. Shipments of pravastatin sodium tablets have been started by Watson, in the 10, 20 and 40 mg strengths.
Watson Pharmaceuticals, Inc. has its headquarters in Corona, CA. It is a leading specialty pharmaceutical company that specializes in the development, manufacture, marketing, and distribution of brand and generic pharmaceutical products. Watson owes its remarkable growth to the company's strategy of combining internal product development along with strategic alliances and synergistic acquisitions of products and businesses.
This Pravastatin sodium is the authorized generic version of Bristol-Myers Squibb's Pravachol(R) product. It consumption has been recommended along with the diet to decrease risks of first heart attack in patients with cardiovascular risks such as elevated cholesterol. It has also been recommended to prevent recurrent heart attack or a stroke in patients with cardiovascular disease especially when diet and exercise are not enough to reverse the symptoms of the disease.
In the year 2005 Pravachol(R) produced sales of approximately $1.7 billion, according to IMS Health data.